
Collegium Pharmaceutical (COLL) Stock Forecast & Price Target
Collegium Pharmaceutical (COLL) Analyst Ratings
Bulls say
Collegium Pharmaceutical Inc. has demonstrated robust revenue growth, reporting a 31% year-over-year increase in net revenue to $209.4 million, exceeding both internal forecasts and market consensus. The company has also shown significant strength in its product line, particularly with Jornay, which experienced a 28.2% sequential revenue growth, driven by a notable 20% year-over-year increase in total prescriptions. The updated guidance for 2025 reflects heightened expectations, with projected top-line revenue increased to between $745 million and $760 million, highlighting ongoing market share gains and promising expansion opportunities within the adult segment.
Bears say
Collegium Pharmaceutical Inc. faces significant challenges that contribute to a negative outlook for its stock, primarily due to declining prescription volumes for key products such as Xtampza ER, Belbuca, and Nucynta, alongside the potential for generic competition disrupting their market positions. Although the company reported an operating cash flow of $78.4 million for the quarter and aims to reduce net leverage below 1.0x by year-end 2025, concerns remain regarding its ability to maintain sales levels and navigate the complexities of reimbursement dynamics in a competitive landscape. Additionally, the reliance on third-party partnerships for product commercialization introduces execution risks that could further impair profitability and regulatory compliance.
This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Collegium Pharmaceutical (COLL) Analyst Forecast & Price Prediction
Start investing in Collegium Pharmaceutical (COLL)
Order type
Buy in
Order amount
Est. shares
0 shares